BAY-985
BAY-985 Basic information
- Product Name:
- BAY-985
- Synonyms:
-
- BAY-985
- 1-Propanone, 1-[4-[(1R)-1-[2-[[6-[6-(dimethylamino)-4-pyrimidinyl]-1H-benzimidazol-2-yl]amino]-4-pyridinyl]ethyl]-1-piperazinyl]-3,3,3-trifluoro-
- BAY-985,IKK,BAY985,IκB kinase,melanoma,IKKε,TBK1,inhibit,I kappa B kinase,Inhibitor,BAY 985,antitumor
- (R)-1-(4-(1-(2-((6-(6-(Dimethylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2-yl)amino)pyridin-4-yl)ethyl)piperazin-1-yl)-3,3,3-trifluoropropan-1-one
- CAS:
- 2409479-29-2
- MF:
- C27H30F3N9O
- MW:
- 553.58
- Mol File:
- 2409479-29-2.mol
BAY-985 Chemical Properties
- Boiling point:
- 753.3±70.0 °C(Predicted)
- Density
- 1.373±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 50 mg/mL (90.32 mM)
- form
- A solid
- pka
- 10.06±0.10(Predicted)
- color
- Light yellow to yellow
BAY-985 Usage And Synthesis
Biological Activity
BAY-985 is a potent and highly selective TBK1/IKKε inhibitor. It is highly potent against TBK1 (IC50 = 2 nM, low ATP assay; 30 nM, high ATP assay) and IKKε (IC50 = 2 nM) and also in mechanocellular phosphorylation of interferon regulatory factor 3 (pIRF3) assays High potency (IC50 = 74 nM) and anti-proliferative effect on SK-MEL-2 cells (IC50 = 900 nM).
in vitro
BAY-985 inhibits FLT3, RSK4, DRAK1, and ULK1 with IC 50 s of 123, 276, 311, and 7930 nM, respectively.
BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 (IRF3) with an IC 50 of 74 nM.
BAY-985 is active in cellular mechanistic assay and shows anti-proliferative activity in a few cancer cells lines with IC 50 s of 900 and 7260 nM for SK-MEL2 (NRAS and TP53 mutated) and ACHN (CDKN2A mutated) cells, respectively.
Cell Proliferation Assay
| Cell Line: | ACHN and SK-MEL-2 cell lines |
| Concentration: | |
| Incubation Time: | td>96 hours |
| Result: | Inhibited proliferation i n SK-MEL2 and ACHN cells with IC 50 s of 900 and 7260 nM, respectively. |
in vivo
BAY-985 (200 mg/kg; po; bid; 111 days) results in weak antitumor efficacy.
BAY-985 shows high clearance (CL b = 4.0 L/h/kg, ca. 95% hepatic extraction), large volume of distribution at steady state (V ss =2.9 L/kg) and a short terminal half-life (t 1 /2 =0.79 h).
| Animal Model: | Female NMRI nude mice bearing SK-MEL-2 human melanoma xenograft model |
| Dosage: | 200 mg/kg |
| Administration: | Applied po; twice daily (bid) continuously 111 days |
| Result: | Treatment resulted in weak antitumor efficacy with a T/C tumor weight ratio of 0.6. The treatment was well tolerated, with a maximum body weight loss of less than 10%. |
target
| Target | Value |
| TBK1 (in low ATP assay) | 2 nM |
| IKKε (Cell-free assay) | 2 nM |
| 30 nM | |
| pIRF3 (Cell-free assay) | 74 nM |
BAY-985Supplier
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 021-58170097
- info@topbiochem.com
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Tel
- 021-52996696，15000506266 15000506266
- Tel
- 021-021-58111628 15800915896
- sales@twochem.com